Last reviewed · How we verify

NCT05191927

A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma

Completed Last updated 14 January 2022
What this trial tests

trial testing male in Thyroid Papillary Carcinoma in 1,200 participants. Completed in 1 August 2021.

Timeline
1 January 2020
Primary endpoint
1 January 2021
1 August 2021

Quick facts

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,200
Start date1 January 2020
Primary completion1 January 2021
Estimated completion1 August 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Eligibility, any sex, with Thyroid Papillary Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish and validate a suitable and practical nomogram for primary hospitals to predict the risk of central lymph node metastasis (CLNM) among thyroid papillary carcinoma (PTC) patients based on clinical and ultrasound characteristics among Chinese population,1000 PTC patients were retrospectively reviewed who underwent bilateral thyroidectomy or lobectomy plus central lymph node dissection(CLND) between June 2014 and September 2019 in Sun Yat-sen Memorial Hospital (Guangzhou, South China), and then LASSO regression analysis was performed to screen out the possible predictors. Another 200 PTC patients from the First Affiliated Hospital of Zhengzhou University (Zhengzhou, North China) who underwent bilateral thyroidectomy or lobectomy plus CLND between March 2019 and November 2020 were enrolled to construct the nomogram. The area under the receiver operating characteristic (ROC) curves (AUC), calibration curves and decision curve analysis (DCA) were used to evaluate the nomogram.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thyroid Papillary Carcinoma

Currently open trials in the same condition.

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing